Targeted Radionuclide Therapy (TRNT) in Modern Cancer Management
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: closed (15 January 2023) | Viewed by 27039
Special Issue Editors
Interests: theranostic radioligands; targeted radionuclide therapies; targeted alpha therapies; combination therapies; molecular imaging; pharmaceutical radiochemistry; coordination and bioinorganic chemistry; radionuclide production and separation methods
Special Issues, Collections and Topics in MDPI journals
Interests: molecular and cell biology; biochemistry; cancer biology; targeted alpha therapies
Special Issue Information
Dear Colleagues,
Targeted radionuclide therapy (TRNT) allows us to deliver various radionuclides to cancer cells in a specific manner. The TRNT approach has been proven clinically highly promising given its experience in the treatment of neuroendocrine tumors or disseminated prostate cancer. The crucial aspect of TRNT is the evaluation of new targets, radionuclides and pharmaceuticals. The mechanisms of resistance and radiation-induced adverse effects limiting patients‘ survival or quality of life must also be addressed.
The purpose of this Special Issue is to host research and review papers on the development and evaluation of TRNT representing this rapidly evolving and highly promising modality of cancer treatment. Areas of interest include, but are not limited to:
- Evaluation of novel targets for cancer treatment and theranostics;
- Design and evaluation of novel radiopharmaceuticals for treatment and theranostics;
- Evaluation of non-standard/exotic radionuclides potentially suitable for TRNT;
- Established and experimental TRNT strategies;
- Targeted alpha therapies;
- Auger-electron radionuclide therapies;
- Radiommunotherapies;
- Prospective combination therapies involving TRNT;
- Biological effects of TRNT;
- Challenges of radiobiology in TRNT;
We look forward to reading your research and breakthroughs in this exciting field and to cover them in this Special Issue.
Dr. Martina Benešová
Dr. Gábor Bakos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Novel and established cancer targets
- therapeutic and theranostic radiopharmaceuticals
- targeted radionuclide therapy
- targeted alpha therapy
- Auger-electron radionuclide therapy
- radiommunotherapy
- combination therapy
- radiobiology
- treatment resistance
- dosimetry
- personalized and precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.